Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

The study will be carried out in partnership with The GOG Foundation and the European Network of Gynecological Oncological ...

Pāpāmoa retiree Marion Henriksen was meant to be travelling in Germany and Austria with a friend. Instead, she had to cancel ...

ASCO 2025 delivered pivotal updates. In this article, we discuss 8 of the more interesting abstracts from an investment ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

A combination of Enhertu and Perjeta nearly doubled progression-free survival compared to standard therapy in data presented ...